1. Home
  2. SOTK vs PLX Comparison

SOTK vs PLX Comparison

Compare SOTK & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sono-Tek Corporation

SOTK

Sono-Tek Corporation

HOLD

Current Price

$3.77

Market Cap

61.6M

Sector

Technology

ML Signal

HOLD

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

HOLD

Current Price

$1.78

Market Cap

204.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOTK
PLX
Founded
1975
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.6M
204.9M
IPO Year
1987
1998

Fundamental Metrics

Financial Performance
Metric
SOTK
PLX
Price
$3.77
$1.78
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
18.3K
510.9K
Earning Date
01-12-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
6.63
N/A
EPS
0.10
0.07
Revenue
$20,607,030.00
$61,840,000.00
Revenue This Year
$2.67
$14.29
Revenue Next Year
$8.20
$16.65
P/E Ratio
$39.59
$25.05
Revenue Growth
N/A
35.41
52 Week Low
$3.23
$1.32
52 Week High
$6.05
$3.10

Technical Indicators

Market Signals
Indicator
SOTK
PLX
Relative Strength Index (RSI) 48.75 42.13
Support Level $3.68 $1.72
Resistance Level $3.84 $1.85
Average True Range (ATR) 0.16 0.09
MACD 0.02 0.02
Stochastic Oscillator 81.39 47.62

Price Performance

Historical Comparison
SOTK
PLX

About SOTK Sono-Tek Corporation

Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Share on Social Networks: